• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 患者在接受静脉-静脉体外膜肺氧合(ECLS)治疗时出现凝血异常会增加技术并发症和支持时间的风险,但对生存率没有影响。

Coagulation abnormalities in patients with COVID-19 on venovenous ECLS increased risk for technical complications and support times but had no impact on survival.

机构信息

Department of Cardiothoracic Surgery, University Hospital Regensburg, Regensburg, Germany.

Department of Anesthesiology, University Hospital Regensburg, Regensburg, Germany.

出版信息

Artif Organs. 2022 Aug;46(8):1669-1681. doi: 10.1111/aor.14218. Epub 2022 Mar 3.

DOI:10.1111/aor.14218
PMID:35192198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9111222/
Abstract

BACKGROUND

Patients with severe coronavirus disease-19 (COVID-19)-associated acute respiratory distress on venovenous extracorporeal lung support (V-V ECLS) showed a high incidence of vascular as well as ECLS-related thrombotic complications. The latter may influence the outcome of the patients.

METHODS

This is a retrospective monocentric study on prospectively collected data of technical complications including 69 adult COVID-19 patients on V-V ECLS (ECLS Registry, March 2020 until April 2021) without and with system exchanges. Alterations in ECLS-specific data, hemolysis, coagulation, and hemostasis parameters were analyzed.

RESULTS

Every second COVID-19 patient on V-V ECLS developed technical complications. Optimized ECLS management at our ECLS center reduced cases of acute clot formation (pump head thrombosis, acute oxygenator thrombosis) (17%), and allowed early identification of progressive clotting processes (worsened gas transfer, coagulation disorder) (14%, 54%) with a significant overhang of hyperfibrinolysis (37%). Although COVID-19 disease and technical complications caused the prolonged length of stay at the intensive care unit and ECLS support times, the proportion of successful weaning and survival rates were comparable with patients without system exchange.

CONCLUSION

The survival of ECLS patients with COVID-19 was independent of the requirement for system exchange due to technical-induced coagulation disorders. Close monitoring for circuit clotting is mandatory in COVID-19 patients and is one prerequisite for successful organ support in these difficult patients.

摘要

背景

接受静脉-静脉体外膜肺氧合(V-V ECMO)治疗的严重 2019 冠状病毒病(COVID-19)相关急性呼吸窘迫综合征患者血管和 ECMO 相关血栓形成并发症发生率较高。后者可能影响患者的预后。

方法

这是一项回顾性单中心研究,对 2020 年 3 月至 2021 年 4 月期间接受 V-V ECMO 治疗的 69 例成年 COVID-19 患者(ECLS 登记处)的前瞻性收集数据进行分析,其中包括无系统更换和有系统更换的患者。分析 ECMO 特定数据、溶血、凝血和止血参数的变化。

结果

每 2 例接受 V-V ECMO 治疗的 COVID-19 患者中就有 1 例发生技术并发症。我们的 ECMO 中心优化 ECMO 管理,降低了急性血栓形成(泵头血栓形成、急性氧合器血栓形成)的发生率(17%),并早期识别出进行性凝血过程(气体交换恶化、凝血障碍)(14%,54%),明显伴有过度纤溶亢进(37%)。尽管 COVID-19 疾病和技术并发症导致重症监护病房和 ECMO 支持时间延长,但成功撤机和存活率与无系统更换的患者相当。

结论

由于技术引起的凝血障碍,COVID-19 患者 ECMO 治疗的存活率与系统更换的需求无关。COVID-19 患者必须密切监测回路凝血情况,这是成功为这些困难患者提供器官支持的前提之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/cd03f1e3b579/AOR-46-1669-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/c1187663a840/AOR-46-1669-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/c765030492ce/AOR-46-1669-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/dd91eb63bd96/AOR-46-1669-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/2449f6989078/AOR-46-1669-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/586ef85878eb/AOR-46-1669-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/cd03f1e3b579/AOR-46-1669-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/c1187663a840/AOR-46-1669-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/c765030492ce/AOR-46-1669-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/dd91eb63bd96/AOR-46-1669-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/2449f6989078/AOR-46-1669-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/586ef85878eb/AOR-46-1669-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/884f/9111222/cd03f1e3b579/AOR-46-1669-g007.jpg

相似文献

1
Coagulation abnormalities in patients with COVID-19 on venovenous ECLS increased risk for technical complications and support times but had no impact on survival.COVID-19 患者在接受静脉-静脉体外膜肺氧合(ECLS)治疗时出现凝血异常会增加技术并发症和支持时间的风险,但对生存率没有影响。
Artif Organs. 2022 Aug;46(8):1669-1681. doi: 10.1111/aor.14218. Epub 2022 Mar 3.
2
Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19.COVID-19 患者行静脉-静脉体外膜肺氧合时的血栓性回路并发症。
J Thromb Thrombolysis. 2021 Feb;51(2):301-307. doi: 10.1007/s11239-020-02217-1.
3
Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange--retrospective analysis of 265 cases.静脉-静脉体外膜肺氧合期间的技术并发症及其与系统更换预测的相关性——265例回顾性分析
PLoS One. 2014 Dec 2;9(12):e112316. doi: 10.1371/journal.pone.0112316. eCollection 2014.
4
Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation.严重 COVID-19 患者体外膜肺氧合抗凝管理。
J Cardiothorac Vasc Anesth. 2021 Feb;35(2):389-397. doi: 10.1053/j.jvca.2020.08.067. Epub 2020 Sep 4.
5
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.仅采用预防性皮下抗凝的静脉-静脉体外膜肺氧合:一项针对60多名患者的观察性研究。
Artif Organs. 2017 Feb;41(2):186-192. doi: 10.1111/aor.12737. Epub 2016 Jun 3.
6
Increased duration and similar outcomes of V-V ECLS in patients with COVID-19 ARDS compared to non-COVID ARDS: Single center experience.与非新冠急性呼吸窘迫综合征患者相比,新冠急性呼吸窘迫综合征患者接受静脉-静脉体外膜肺氧合治疗的时间延长且预后相似:单中心经验
Artif Organs. 2023 Apr;47(4):731-739. doi: 10.1111/aor.14463. Epub 2022 Dec 2.
7
COVID-19 and Extracorporeal Membrane Oxygenation.新型冠状病毒肺炎与体外膜肺氧合
Adv Exp Med Biol. 2021;1353:173-195. doi: 10.1007/978-3-030-85113-2_10.
8
Venovenous extracorporeal life support circuit exchange: Tips and pitfalls.静脉-静脉体外生命支持回路更换:技巧与陷阱。
Multimed Man Cardiothorac Surg. 2022 Feb 17;2022. doi: 10.1510/mmcts.2022.006.
9
Different mechanisms of oxygenator failure and high plasma von Willebrand factor antigen influence success and survival of venovenous extracorporeal membrane oxygenation.不同的氧合器故障机制和高血浆血管性血友病因子抗原影响静脉-静脉体外膜肺氧合的成功率和存活率。
PLoS One. 2021 Mar 18;16(3):e0248645. doi: 10.1371/journal.pone.0248645. eCollection 2021.
10
Current knowledge gaps in extracorporeal respiratory support.体外呼吸支持方面当前的知识空白。
Intensive Care Med Exp. 2023 Nov 14;11(1):77. doi: 10.1186/s40635-023-00563-x.

引用本文的文献

1
Thrombocytopenia During Venovenous Extracorporeal Membrane Oxygenation in Adult Patients With Bacterial, Viral, and COVID-19 Pneumonia.成人细菌性、病毒性和新冠肺炎肺炎患者在静脉-静脉体外膜肺氧合期间的血小板减少症
ASAIO J. 2025 Jun 1;71(6):498-509. doi: 10.1097/MAT.0000000000002383. Epub 2025 Jan 28.
2
Incidence of neutrophil extracellular traps (NETs) in different membrane oxygenators: pilot in vitro experiments in commercially available coated membranes.不同膜式氧合器中中性粒细胞胞外陷阱(NETs)的发生率:市售涂层膜的体外初步实验
J Artif Organs. 2025 Jan 8. doi: 10.1007/s10047-024-01486-4.
3
Neutrophil extracellular traps - a potential trigger for the development of thrombocytopenia during extracorporeal membrane oxygenation.

本文引用的文献

1
Assessment of 28-Day In-Hospital Mortality in Mechanically Ventilated Patients With Coronavirus Disease 2019: An International Cohort Study.2019年冠状病毒病机械通气患者28天院内死亡率评估:一项国际队列研究
Crit Care Explor. 2021 Nov 5;3(11):e0567. doi: 10.1097/CCE.0000000000000567. eCollection 2021 Nov.
2
Outcomes after extracorporeal membrane oxygenation support in COVID-19 and non-COVID-19 patients.COVID-19 与非 COVID-19 患者体外膜肺氧合支持后的结局。
Artif Organs. 2022 Apr;46(4):688-696. doi: 10.1111/aor.14090. Epub 2021 Nov 4.
3
Extracorporeal membrane oxygenation in the management of critically ill patients with coronavirus disease 2019: A narrative review.
中性粒细胞胞外诱捕网 - 体外膜肺氧合期间血小板减少症发展的潜在触发因素。
Front Immunol. 2024 Feb 21;15:1339235. doi: 10.3389/fimmu.2024.1339235. eCollection 2024.
体外膜肺氧合在2019冠状病毒病危重症患者管理中的应用:一项叙述性综述。
Exp Ther Med. 2021 Nov;22(5):1296. doi: 10.3892/etm.2021.10731. Epub 2021 Sep 14.
4
Evolving outcomes of extracorporeal membrane oxygenation support for severe COVID-19 ARDS in Sorbonne hospitals, Paris.巴黎索邦大学医院严重 COVID-19 急性呼吸窘迫综合征体外膜肺氧合支持的治疗结果演变。
Crit Care. 2021 Oct 9;25(1):355. doi: 10.1186/s13054-021-03780-6.
5
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry.COVID-19 患者的体外膜肺氧合治疗:国际体外生命支持组织注册研究的结果演变。
Lancet. 2021 Oct 2;398(10307):1230-1238. doi: 10.1016/S0140-6736(21)01960-7. Epub 2021 Sep 29.
6
Outcomes of extracorporeal membrane oxygenation in influenza versus COVID-19 during the first wave of COVID-19.COVID-19 大流行第一波期间,体外膜肺氧合治疗流感与 COVID-19 的结局比较。
J Card Surg. 2021 Oct;36(10):3740-3746. doi: 10.1111/jocs.15888. Epub 2021 Aug 9.
7
Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study.在接受静脉-静脉体外膜肺氧合治疗的患者中,无肝素诱导血小板减少症的患者中,阿加曲班与肝素的比较:一项倾向评分匹配研究。
Crit Care. 2021 Apr 29;25(1):160. doi: 10.1186/s13054-021-03581-x.
8
Extracorporeal Membrane Oxygenation in Patients With COVID-19: An International Multicenter Cohort Study.COVID-19患者的体外膜肺氧合:一项国际多中心队列研究
J Intensive Care Med. 2021 Aug;36(8):910-917. doi: 10.1177/08850666211007063. Epub 2021 Apr 7.
9
Hypercoagulopathy, acquired coagulation disorders and anticoagulation before, during and after extracorporeal membrane oxygenation in COVID-19: a case series.COVID-19 患者体外膜肺氧合治疗前、中、后发生的高凝状态、获得性凝血障碍和抗凝治疗:病例系列研究。
Perfusion. 2021 Sep;36(6):592-602. doi: 10.1177/02676591211001791. Epub 2021 Mar 15.
10
Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization.体外膜肺氧合治疗 COVID-19:体外生命支持组织 2021 年更新指南。
ASAIO J. 2021 May 1;67(5):485-495. doi: 10.1097/MAT.0000000000001422.